LAUSR

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy, and the key risk factors include infection with the hepatitis B virus (HBV), hepatitis C virus, metabolic syndrome and alcoholism. The overall prognosis of HCC is poor, with a 50%–70% rate of tumour recurrence despite interventions such as surgical resection and radiofrequency ablation. Recently, a novel histological subtype of HCC designated as the ‘macrotrabecular massive’ variant (MTM‐HCC) was described by Calderaro et al.[1] MTM‐HCC is associated with poor survival and early recurrence, underscoring the need to recognise this clinically aggressive variant in order to better manage the disease.[2]